{"title":"Crossing by or effective BYCROSSing in long & calcified peripheral lesions with a <i>New Kid on the Block?</i>","authors":"Grigorios Korosoglou, Christos Rammos, Erwin Blessing","doi":"10.1024/0301-1526/a001150","DOIUrl":"https://doi.org/10.1024/0301-1526/a001150","url":null,"abstract":"","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":"53 6","pages":"363-365"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-07-17DOI: 10.1024/0301-1526/a001137
Matija Kozak, Pavel Poredoš, Aleš Blinc, Mateja Kaja Ježovnik, Peter Poredoš
Peripheral arterial disease (PAD) represents one of the most frequent manifestations of atherosclerosis in men and women. In both sexes, PAD is related to classical risk factors of atherosclerosis, which are similarly distributed, but some additional factors determine differences between men and women. More frequent asymptomatic disease in women than in men and less frequent screening in women may result in a false underestimation of the prevalence of PAD in women. All these factors may cause delayed diagnosis and treatment of PAD in women. Estrogen hormones have vasoprotective properties that lower the prevalence of atherosclerosis in women of younger age. However, estrogen probably does not have a protective role against the development of cardiovascular disease in women of an older age. Hormone replacement therapy (HRT) of less than one year does not appear to reduce the odds of developing PAD in postmenopausal women. It may even increase the risk of morbidity from vascular interventions. However, some studies indicated that HRT for more than one year significantly decreases the risk of PAD if administered early after the last menstruation. Also, treatment of PAD in women differs to some extent from men.
外周动脉疾病(PAD)是男性和女性动脉粥样硬化最常见的表现之一。在男女两性中,PAD 都与动脉粥样硬化的传统风险因素有关,这些因素的分布情况相似,但一些额外的因素决定了男女之间的差异。与男性相比,女性无症状疾病的发生率更高,女性筛查的频率更低,这些都可能导致女性 PAD 患病率被错误低估。所有这些因素都可能导致女性 PAD 诊断和治疗的延误。雌激素荷尔蒙具有血管保护作用,可降低年轻女性动脉粥样硬化的发病率。但是,雌激素对老年妇女心血管疾病的发生可能没有保护作用。少于一年的激素替代疗法(HRT)似乎不会降低绝经后妇女罹患 PAD 的几率。它甚至可能增加血管介入治疗的发病风险。然而,一些研究表明,如果在末次月经后尽早进行一年以上的人工流产治疗,则可显著降低 PAD 的风险。此外,女性 PAD 的治疗在一定程度上也与男性不同。
{"title":"Peripheral arterial disease in women.","authors":"Matija Kozak, Pavel Poredoš, Aleš Blinc, Mateja Kaja Ježovnik, Peter Poredoš","doi":"10.1024/0301-1526/a001137","DOIUrl":"10.1024/0301-1526/a001137","url":null,"abstract":"<p><p><b></b> Peripheral arterial disease (PAD) represents one of the most frequent manifestations of atherosclerosis in men and women. In both sexes, PAD is related to classical risk factors of atherosclerosis, which are similarly distributed, but some additional factors determine differences between men and women. More frequent asymptomatic disease in women than in men and less frequent screening in women may result in a false underestimation of the prevalence of PAD in women. All these factors may cause delayed diagnosis and treatment of PAD in women. Estrogen hormones have vasoprotective properties that lower the prevalence of atherosclerosis in women of younger age. However, estrogen probably does not have a protective role against the development of cardiovascular disease in women of an older age. Hormone replacement therapy (HRT) of less than one year does not appear to reduce the odds of developing PAD in postmenopausal women. It may even increase the risk of morbidity from vascular interventions. However, some studies indicated that HRT for more than one year significantly decreases the risk of PAD if administered early after the last menstruation. Also, treatment of PAD in women differs to some extent from men.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":"366-370"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141627782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-08-29DOI: 10.1024/0301-1526/a001146
Panagiotis Kanavaros, Georgios Karatzias, Alexandra Papoudou-Bai, Alexandra Barbouti, Theodoros Troupis
The anatomical variability of the thoracic duct and the right lymphatic duct predisposes them to inadvertent damage following head and neck surgery thereby leading to chyle leak which is an uncommon complication with potentially significant associated morbidity. Although chyle leak is predominately associated with left-sided neck surgery, it also occurs as a complication of the right-sided neck dissection. Variable figures concerning chyle leakage after right-sided neck dissections were reported, ranging from 0 per cent to higher prevalences such as 14%, 24%, 33% and 60% of total cases of chyle leakages associated with neck surgery. The right-sided complications may implicate the right lymphatic duct and right-sided terminations of the thoracic duct into the venous system which occur in about 1-6% of humans. Other clinically relevant conditions involving the right-sided major lymphatic vessels include chyle leaks following right anterior cervical spine surgery, cysts of the right lymphatic duct and dilatation of the right lymphatic duct in the setting of recurrent cervical swelling. This article presents a review of the literature concerning the basic anatomy and the clinical relevance of the right lymphatic duct and the right-sided terminations of the thoracic duct into the venous circulation.
{"title":"The right lymphatic duct: basic anatomy and clinical relevance.","authors":"Panagiotis Kanavaros, Georgios Karatzias, Alexandra Papoudou-Bai, Alexandra Barbouti, Theodoros Troupis","doi":"10.1024/0301-1526/a001146","DOIUrl":"10.1024/0301-1526/a001146","url":null,"abstract":"<p><p><b></b> The anatomical variability of the thoracic duct and the right lymphatic duct predisposes them to inadvertent damage following head and neck surgery thereby leading to chyle leak which is an uncommon complication with potentially significant associated morbidity. Although chyle leak is predominately associated with left-sided neck surgery, it also occurs as a complication of the right-sided neck dissection. Variable figures concerning chyle leakage after right-sided neck dissections were reported, ranging from 0 per cent to higher prevalences such as 14%, 24%, 33% and 60% of total cases of chyle leakages associated with neck surgery. The right-sided complications may implicate the right lymphatic duct and right-sided terminations of the thoracic duct into the venous system which occur in about 1-6% of humans. Other clinically relevant conditions involving the right-sided major lymphatic vessels include chyle leaks following right anterior cervical spine surgery, cysts of the right lymphatic duct and dilatation of the right lymphatic duct in the setting of recurrent cervical swelling. This article presents a review of the literature concerning the basic anatomy and the clinical relevance of the right lymphatic duct and the right-sided terminations of the thoracic duct into the venous circulation.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":"371-377"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-10-11DOI: 10.1024/0301-1526/a001155
Nataliya Kasimovskaya, Elena Fomina, Maria Krivetskaya, Ekaterina Diatlova, Elena Egorova, Dmitry Pavlov
Background: To compare the effectiveness of digital phenotyping of patients diagnosed with arterial hypertension with traditional monitoring methods over a three-year period. Patients and methods: The study was conducted from January 2021 to January 2024 among 800 patients diagnosed with arterial hypertension at 6 clinics in Moscow, Russia, evenly divided into experimental (identification of digital biomarkers of disease progression for digital phenotyping) and control (standard monitoring methods) groups. The intervention included lifestyle changes focused on increasing physical activity, improving sleep quality, reducing stress, and modifying diet. Significant improvements were observed in the experimental group compared to the control group. Systolic blood pressure decreased by 10 mmHg (p<0.001), pulse by 5 beats per minute (p<0.001), and stress level by 2 points (p<0.001) in the experimental group. Additionally, physical activity increased by 15 minutes per day (p<0.001), and sleep quality improved by 2 points on a scale from 1 to 10 (p<0.001). Results: Multiple regression analysis showed a decrease in the significance of digital biomarkers over the study period, indicating a positive response to the intervention. Conclusions: The obtained results emphasize the importance of comprehensive interventions in managing arterial hypertension and its related conditions. Implementing comprehensive lifestyle changes can lead to significant health improvements and serve as an effective preventive strategy. Further research is needed to explore optimal intervention strategies for promoting societal health.
{"title":"Determination of digital biomarkers of disease progression for digital phenotyping of patients with arterial hypertension.","authors":"Nataliya Kasimovskaya, Elena Fomina, Maria Krivetskaya, Ekaterina Diatlova, Elena Egorova, Dmitry Pavlov","doi":"10.1024/0301-1526/a001155","DOIUrl":"10.1024/0301-1526/a001155","url":null,"abstract":"<p><p><b></b> <i>Background:</i> To compare the effectiveness of digital phenotyping of patients diagnosed with arterial hypertension with traditional monitoring methods over a three-year period. <i>Patients and methods:</i> The study was conducted from January 2021 to January 2024 among 800 patients diagnosed with arterial hypertension at 6 clinics in Moscow, Russia, evenly divided into experimental (identification of digital biomarkers of disease progression for digital phenotyping) and control (standard monitoring methods) groups. The intervention included lifestyle changes focused on increasing physical activity, improving sleep quality, reducing stress, and modifying diet. Significant improvements were observed in the experimental group compared to the control group. Systolic blood pressure decreased by 10 mmHg (<i>p</i><0.001), pulse by 5 beats per minute (<i>p</i><0.001), and stress level by 2 points (<i>p</i><0.001) in the experimental group. Additionally, physical activity increased by 15 minutes per day (<i>p</i><0.001), and sleep quality improved by 2 points on a scale from 1 to 10 (<i>p</i><0.001). <i>Results:</i> Multiple regression analysis showed a decrease in the significance of digital biomarkers over the study period, indicating a positive response to the intervention. <i>Conclusions:</i> The obtained results emphasize the importance of comprehensive interventions in managing arterial hypertension and its related conditions. Implementing comprehensive lifestyle changes can lead to significant health improvements and serve as an effective preventive strategy. Further research is needed to explore optimal intervention strategies for promoting societal health.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":"428-436"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: A potential independent association between arterial stiffness (AS) and the development of new-onset chronic kidney disease (CKD) has not been thoroughly examined. Patients and methods: A total of 6929 participants were collected from the Kailuan study. All participants were free of CKD at the baseline. The participants were divided into four groups based on their brachial-ankle pulse wave velocity (baPWV) values. Cox regression models were used to analyze the relationship between baPWV values and the risk of new-onset CKD. Results: Over the course of a 10.06-year follow-up period, a total of 962 cases of new-onset CKD were documented. Cox proportional hazards analyses showed that a higher baPWV quartile was linked to an increased risk of new-onset CKD. Conclusions: Brachial-ankle pulse wave velocity has a strong correlation with the development of new-onset CKD. Therefore, baPWV can be considered an innovative indicator for predicting the occurrence of new-onset CKD.
{"title":"Arterial stiffness is associated with new-onset chronic kidney disease.","authors":"Kangbo Li, Qi Qi, Xinyi Li, Liying Tian, Liyan Wang, Shouling Wu, Quanle Han","doi":"10.1024/0301-1526/a001142","DOIUrl":"10.1024/0301-1526/a001142","url":null,"abstract":"<p><p><b></b> <i>Background</i>: A potential independent association between arterial stiffness (AS) and the development of new-onset chronic kidney disease (CKD) has not been thoroughly examined. <i>Patients and methods:</i> A total of 6929 participants were collected from the Kailuan study. All participants were free of CKD at the baseline. The participants were divided into four groups based on their brachial-ankle pulse wave velocity (baPWV) values. Cox regression models were used to analyze the relationship between baPWV values and the risk of new-onset CKD. <i>Results:</i> Over the course of a 10.06-year follow-up period, a total of 962 cases of new-onset CKD were documented. Cox proportional hazards analyses showed that a higher baPWV quartile was linked to an increased risk of new-onset CKD. <i>Conclusions:</i> Brachial-ankle pulse wave velocity has a strong correlation with the development of new-onset CKD. Therefore, baPWV can be considered an innovative indicator for predicting the occurrence of new-onset CKD.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":"420-427"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-30DOI: 10.1024/0301-1526/a001154
Moritz Wegner, Reinier R Smeets, Leo F Veenstra, Wael Ahmad, Amelie L Behrens, Florian Kursch, Hendrik Wienemann, Bernhard Dorweiler, Stephan Baldus, Matti Adam, Barend M E Mees, Max M Meertens
Background: Transcatheter aortic valve implantation (TAVI) via transfemoral (TF) access is increasingly integral to aortic valve disease treatment, expanding beyond high-risk patients. Despite technical advancements, access-related vascular complications, occurring in approximately 10% of TAVI procedures, remain a substantial challenge. Objective: This study investigated the clinical and morphological characteristics of percutaneous TF-TAVI patients experiencing occlusive (OC) and hemorrhagic (HC) complications managed with surgical or endovascular reintervention. Methods: The cohort included patients from a Dutch and a German tertiary referral hospital, managed with TF-TAVI procedures between 2017 and 2021 that required reintervention for OC or HC. Demographics, comorbidities, procedural details, and preoperative imaging data were collected and compared between groups. Results: Among 109 TF-TAVI patients, 32 with OC and 77 with HC required reintervention. The OC group presented significantly smaller access arterial diameters (common femoral artery: OC 6.7 mm vs. HC 8.9 mm, p<.001; external iliac artery: OC 7.2 mm vs. HC 8.3 mm, p<.001; common iliac artery: OC 9.4 mm vs. HC 10.5 mm, p=.012) while the HC group presented higher tortuosity index (TI) (OC 1.24 vs. HC 1.30; p=.017). No differences were observed regarding baseline characteristics, vessel calcification or vascular closure device use. Conclusions: In patients requiring reintervention following TF-TAVI, smaller arterial diameters were associated with OC, while higher TI was linked to HC. These findings emphasize the importance of preoperative imaging in developing individualized prevention strategies.
背景:通过经股动脉(TF)入路进行经导管主动脉瓣植入术(TAVI)越来越成为主动脉瓣疾病治疗中不可或缺的一部分,其范围已超出高风险患者。尽管技术不断进步,但与入路相关的血管并发症仍是一个巨大的挑战,约有 10% 的 TAVI 手术会出现血管并发症。研究目的本研究调查了发生闭塞(OC)和出血(HC)并发症并接受手术或血管内再介入治疗的经皮 TF-TAVI 患者的临床和形态特征。方法:研究对象包括一家荷兰和一家德国三级转诊医院的患者,这些患者在2017年至2021年间接受了TF-TAVI手术,并因OC或HC而需要再次介入治疗。收集人口统计学、合并症、手术细节和术前影像学数据,并进行组间比较。结果:在109例TF-TAVI患者中,32例OC患者和77例HC患者需要再次介入治疗。OC组的入路动脉直径明显较小(股总动脉:OC 6.7 mm vs. HC 8.9 mm,ppp=.012),而HC组的迂曲指数(TI)较高(OC 1.24 vs. HC 1.30;pp=.017)。在基线特征、血管钙化或使用血管闭合装置方面未观察到差异。结论在TF-TAVI术后需要再次介入的患者中,较小的动脉直径与OC相关,而较高的TI与HC相关。这些发现强调了术前成像在制定个体化预防策略中的重要性。
{"title":"Comparison of patients with occlusive or hemorrhagic access site complications requiring reintervention after percutaneous transfemoral transcatheter aortic valve implantation.","authors":"Moritz Wegner, Reinier R Smeets, Leo F Veenstra, Wael Ahmad, Amelie L Behrens, Florian Kursch, Hendrik Wienemann, Bernhard Dorweiler, Stephan Baldus, Matti Adam, Barend M E Mees, Max M Meertens","doi":"10.1024/0301-1526/a001154","DOIUrl":"https://doi.org/10.1024/0301-1526/a001154","url":null,"abstract":"<p><p><b></b> <i>Background:</i> Transcatheter aortic valve implantation (TAVI) via transfemoral (TF) access is increasingly integral to aortic valve disease treatment, expanding beyond high-risk patients. Despite technical advancements, access-related vascular complications, occurring in approximately 10% of TAVI procedures, remain a substantial challenge. <i>Objective:</i> This study investigated the clinical and morphological characteristics of percutaneous TF-TAVI patients experiencing occlusive (OC) and hemorrhagic (HC) complications managed with surgical or endovascular reintervention. <i>Methods:</i> The cohort included patients from a Dutch and a German tertiary referral hospital, managed with TF-TAVI procedures between 2017 and 2021 that required reintervention for OC or HC. Demographics, comorbidities, procedural details, and preoperative imaging data were collected and compared between groups. <i>Results:</i> Among 109 TF-TAVI patients, 32 with OC and 77 with HC required reintervention. The OC group presented significantly smaller access arterial diameters (common femoral artery: OC 6.7 mm vs. HC 8.9 mm, <i>p</i><.001; external iliac artery: OC 7.2 mm vs. HC 8.3 mm, <i>p</i><.001; common iliac artery: OC 9.4 mm vs. HC 10.5 mm, <i>p</i>=.012) while the HC group presented higher tortuosity index (TI) (OC 1.24 vs. HC 1.30; <i>p</i>=.017). No differences were observed regarding baseline characteristics, vessel calcification or vascular closure device use. <i>Conclusions:</i> In patients requiring reintervention following TF-TAVI, smaller arterial diameters were associated with OC, while higher TI was linked to HC. These findings emphasize the importance of preoperative imaging in developing individualized prevention strategies.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-08-29DOI: 10.1024/0301-1526/a001145
Simon Wolf, Stefano Barco, Marcello Di Nisio, Charles E Mahan, Konstantinos C Christodoulou, Sophie Ter Haar, Stavros Konstantinides, Nils Kucher, Frederikus A Klok, Suzanne C Cannegieter, Luca Valerio
Deep vein thrombosis (DVT) is a cause of considerable morbidity worldwide. It is a common clinical disease in the daily practice of several medical disciplines including general medicine, angiology, and internal medicine, as well as of interest to public health because of its preventability and its sensitivity to secular changes in the distribution of population risk factors. In this review we present a comprehensive overview of the epidemiological features of DVT, including incidence and risk factors. Additionally, we give an overview of the burden that DVT poses on modern health care systems.
{"title":"Epidemiology of deep vein thrombosis.","authors":"Simon Wolf, Stefano Barco, Marcello Di Nisio, Charles E Mahan, Konstantinos C Christodoulou, Sophie Ter Haar, Stavros Konstantinides, Nils Kucher, Frederikus A Klok, Suzanne C Cannegieter, Luca Valerio","doi":"10.1024/0301-1526/a001145","DOIUrl":"10.1024/0301-1526/a001145","url":null,"abstract":"<p><p><b></b> Deep vein thrombosis (DVT) is a cause of considerable morbidity worldwide. It is a common clinical disease in the daily practice of several medical disciplines including general medicine, angiology, and internal medicine, as well as of interest to public health because of its preventability and its sensitivity to secular changes in the distribution of population risk factors. In this review we present a comprehensive overview of the epidemiological features of DVT, including incidence and risk factors. Additionally, we give an overview of the burden that DVT poses on modern health care systems.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":"298-307"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-07-17DOI: 10.1024/0301-1526/a001138
Gualtiero Palareti, Davide Santagata, Chiara De Ponti, Walter Ageno, Paolo Prandoni
The treatment of proximal deep vein thrombosis (DVT) of the lower limbs includes an initial management phase, covering the first 1 to 3 weeks, a primary treatment phase, lasting a minimum of 3 months, and a secondary treatment phase for those patients requiring continuing anticoagulation beyond the first 3 to 6 months. During the initial phase most patients with DVT can be managed as outpatients. Exclusion criteria for home treatment include high risk of bleeding, limb threatening DVT or other conditions requiring hospitalisation. Anticoagulant drugs represent the mainstay of treatment and include parenteral drugs such as unfractionated heparin or low molecular weight heparin, and oral drugs such as the vitamin K antagonists and the direct oral anticoagulants (DOACs). DOACs are currently recommended as the first line of treatment for proximal DVT of the lower limbs, with no preference for one DOAC over another. Factors to consider when choosing the anticoagulant strategy include, among others, renal and liver function, underlying diseases such as cancer or the antiphospholipid syndrome, and patient preferences. Indefinite duration of anticoagulation beyond the first 3 to 6 months is recommended for patients with unprovoked DVT and patients with permanent, chronic risk factors. Two DOACs, namely apixaban and rivaroxaban, can be administered at low doses for the secondary prevention of DVT. Elastic compression stockings (ECS) have been used for decades in patients with proximal DVT with the aim of counteracting the venous hypertension generated by the vascular disorder and reducing leg edema and to prevent the post-thrombotic syndrome.
{"title":"Anticoagulation and compression therapy for proximal acute deep vein thrombosis.","authors":"Gualtiero Palareti, Davide Santagata, Chiara De Ponti, Walter Ageno, Paolo Prandoni","doi":"10.1024/0301-1526/a001138","DOIUrl":"10.1024/0301-1526/a001138","url":null,"abstract":"<p><p><b></b> The treatment of proximal deep vein thrombosis (DVT) of the lower limbs includes an initial management phase, covering the first 1 to 3 weeks, a primary treatment phase, lasting a minimum of 3 months, and a secondary treatment phase for those patients requiring continuing anticoagulation beyond the first 3 to 6 months. During the initial phase most patients with DVT can be managed as outpatients. Exclusion criteria for home treatment include high risk of bleeding, limb threatening DVT or other conditions requiring hospitalisation. Anticoagulant drugs represent the mainstay of treatment and include parenteral drugs such as unfractionated heparin or low molecular weight heparin, and oral drugs such as the vitamin K antagonists and the direct oral anticoagulants (DOACs). DOACs are currently recommended as the first line of treatment for proximal DVT of the lower limbs, with no preference for one DOAC over another. Factors to consider when choosing the anticoagulant strategy include, among others, renal and liver function, underlying diseases such as cancer or the antiphospholipid syndrome, and patient preferences. Indefinite duration of anticoagulation beyond the first 3 to 6 months is recommended for patients with unprovoked DVT and patients with permanent, chronic risk factors. Two DOACs, namely apixaban and rivaroxaban, can be administered at low doses for the secondary prevention of DVT. Elastic compression stockings (ECS) have been used for decades in patients with proximal DVT with the aim of counteracting the venous hypertension generated by the vascular disorder and reducing leg edema and to prevent the post-thrombotic syndrome.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":"289-297"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141627778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-07-17DOI: 10.1024/0301-1526/a001134
Max Jonathan Stumpf, Tim Winkler, Marit Siebigteroth, Annemarie Lenzen, Leonie Weinhold, Georg Nickenig, Doris Hendig, Dirk Skowasch, Nadjib Schahab, Christian A Schaefer
Background: Pseudoxanthoma elasticum (PXE) is a rare, inherited disease characterised by specific skin lesions, progressive loss of vision and early onset atherosclerosis. Atherosclerosis in PXE leads to an increased rate of vascular occlusion and severe intermittent claudication. Although genetically determined, the individual course of PXE is highly variable. Up to now, there is no sufficient parameter to identify individuals at risk of rapid disease progression. This present study focused the lipid profile of patients with PXE and its possible influence on the clinical severity of peripheral artery disease (PAD). Patients and methods: 112 patients with PXE were retrospectively screened. Patients without a complete lipid profile consisting of total cholesterol (TC), triglycerides (TGC), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and Lipoprotein(a) (Lp[a]) where excluded as well as patients with already initiated lipid-lowering therapy. 52 patients met the inclusion criteria. An age-adjusted ordinal regression model was applied to determine the association of each lipid fraction with the severity of PAD assessed as Fontaine classification. Results: The lipid profile of patients with PXE was unremarkable (TGC: 135.8±105.8 mg/dl; TC: 172.5±44.4 mg/dl; HDL: 63.0±18.2 mg/dl; Lp[a]: 64.7±93.5 nmol/l). Ordinal regression showed a significant association of Lp(a) with the severity of PAD with an odds ratio of 1.01 (1.00-1.02; p = 0.004), whereas the other fractions of the lipid profile had no significant influence. Conclusions: This study provides the largest evaluation of blood lipids up to now and the first characterization of Lp(a) levels in patients with PXE. We were able to provide first evidence of a correlation between elevated levels of Lp(a) and the severity of PAD. The present results suggest that determination of Lp(a) in early stages of PXE could help to identify patients at risk of rapid disease progression and with the need of intensified walking exercise training.
背景:假黄疽(PXE)是一种罕见的遗传性疾病,其特征是特殊的皮肤损伤、进行性视力丧失和早发性动脉粥样硬化。PXE 中的动脉粥样硬化会导致血管闭塞率升高和严重的间歇性跛行。虽然 PXE 是由基因决定的,但其个体病程变化很大。到目前为止,还没有足够的参数来识别疾病快速进展的风险个体。本研究的重点是 PXE 患者的血脂状况及其对外周动脉疾病(PAD)临床严重程度的可能影响。患者和方法:对 112 名 PXE 患者进行了回顾性筛查。排除了没有完整血脂谱(包括总胆固醇(TC)、甘油三酯(TGC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)和脂蛋白(a)(Lp[a]))的患者以及已经开始降脂治疗的患者。52 名患者符合纳入标准。应用年龄调整后的序数回归模型来确定每种血脂组分与根据方丹分级评估的 PAD 严重程度之间的关系。结果PXE患者的血脂谱无异常(TGC:135.8±105.8 mg/dl;TC:172.5±44.4 mg/dl;HDL:63.0±18.2 mg/dl;Lp[a]:64.7±93.5 nmol/l)。正回归结果显示,脂蛋白[a]与 PAD 的严重程度有显著相关性,几率比为 1.01 (1.00-1.02; p = 0.004),而血脂组合的其他部分则没有显著影响。结论:这项研究提供了迄今为止最大规模的血脂评估,并首次描述了 PXE 患者的脂蛋白(a)水平。我们首次证明了脂蛋白(a)水平升高与 PAD 严重程度之间的相关性。本研究结果表明,在 PXE 早期阶段测定脂蛋白(a)有助于识别有疾病快速进展风险和需要加强步行锻炼训练的患者。
{"title":"Influence of pseudoxanthoma elasticum on the lipid profile and prognostic implications.","authors":"Max Jonathan Stumpf, Tim Winkler, Marit Siebigteroth, Annemarie Lenzen, Leonie Weinhold, Georg Nickenig, Doris Hendig, Dirk Skowasch, Nadjib Schahab, Christian A Schaefer","doi":"10.1024/0301-1526/a001134","DOIUrl":"10.1024/0301-1526/a001134","url":null,"abstract":"<p><p><b></b> <i>Background:</i> Pseudoxanthoma elasticum (PXE) is a rare, inherited disease characterised by specific skin lesions, progressive loss of vision and early onset atherosclerosis. Atherosclerosis in PXE leads to an increased rate of vascular occlusion and severe intermittent claudication. Although genetically determined, the individual course of PXE is highly variable. Up to now, there is no sufficient parameter to identify individuals at risk of rapid disease progression. This present study focused the lipid profile of patients with PXE and its possible influence on the clinical severity of peripheral artery disease (PAD). <i>Patients and methods:</i> 112 patients with PXE were retrospectively screened. Patients without a complete lipid profile consisting of total cholesterol (TC), triglycerides (TGC), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and Lipoprotein(a) (Lp[a]) where excluded as well as patients with already initiated lipid-lowering therapy. 52 patients met the inclusion criteria. An age-adjusted ordinal regression model was applied to determine the association of each lipid fraction with the severity of PAD assessed as Fontaine classification. <i>Results:</i> The lipid profile of patients with PXE was unremarkable (TGC: 135.8±105.8 mg/dl; TC: 172.5±44.4 mg/dl; HDL: 63.0±18.2 mg/dl; Lp[a]: 64.7±93.5 nmol/l). Ordinal regression showed a significant association of Lp(a) with the severity of PAD with an odds ratio of 1.01 (1.00-1.02; p = 0.004), whereas the other fractions of the lipid profile had no significant influence. <i>Conclusions:</i> This study provides the largest evaluation of blood lipids up to now and the first characterization of Lp(a) levels in patients with PXE. We were able to provide first evidence of a correlation between elevated levels of Lp(a) and the severity of PAD. The present results suggest that determination of Lp(a) in early stages of PXE could help to identify patients at risk of rapid disease progression and with the need of intensified walking exercise training.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":"352-357"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141627780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}